02Oct 2022
A 96‐Week, Double‐Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults

A 96‐Week, Double‐Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults

To compare the effects of bexagliflozin tablets, 20 mg, with those of optimally titrated glimepiride when used to treat adults with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin. Adults with type 2 diabetes (n = 426) taking metformin and having an HbA1c between 7.0% and 10.5% were randomized to receive bexagliflozin tablets, 20 mg, or titrated glimepiride. Bexagliflozin was non‐inferior to glimepiride in lowering HbA1c, was superior to glimepiride for decreases in body mass and SBP, and was associated with significantly fewer hypoglycemic events than glimepiride. A favorable effect on glomerular filtration rate was observed.

  • #endo-diabetology

Like

Save

Share